Ensysce Biosciences, Inc. reports developments as a clinical-stage pharmaceutical company focused on pain and central nervous system therapeutics designed to reduce opioid abuse and overdose risk. Its recurring updates center on the TAAP™ (Trypsin-Activated Abuse Protection) prodrug platform, the MPAR® (Multi-Pill Abuse Resistance) overdose-protection platform, and product candidates including PF614 and PF614-MPAR.
Company news also covers clinical-study progress, FDA-related designations and regulatory engagement, peer-reviewed data, scientific conference presentations, intellectual-property updates, financing transactions, financial results, Nasdaq compliance matters, board and governance changes, and strategic-review disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.